Trial Profile
A Clinical Trial to Assess the Effects of Ustekinumab and Etanercept on Skin and Blood Biomarkers of Psoriasis in Patients With Moderate to Severe Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary) ; Etanercept
- Indications Plaque psoriasis
- Focus Biomarker; Pharmacodynamics
- Sponsors Merck & Co
- 17 Jan 2012 Actual end date (December 2011) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.